Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial

AIM: To assess patient‐reported outcomes (PROs) in the SoliMix trial, which compared the efficacy and safety of iGlarLixi versus BIAsp 30 in people with type 2 diabetes (T2D). MATERIALS AND METHODS: SoliMix (EudraCT: 2017‐003370‐13), a 26‐week, open‐label study, randomized (1:1) 887 adults with T2D...

Descripción completa

Detalles Bibliográficos
Autores principales: Polonsky, William H., Giorgino, Francesco, Rosenstock, Julio, Whitmire, Katherine, Lew, Elisheva, Coudert, Mathieu, Alvarez, Agustina, Nicholls, Charlie, McCrimmon, Rory J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805099/
https://www.ncbi.nlm.nih.gov/pubmed/36053820
http://dx.doi.org/10.1111/dom.14822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805099/
https://www.ncbi.nlm.nih.gov/pubmed/36053820
http://dx.doi.org/10.1111/dom.14822

Ejemplares similares